DK148478B - 4-hydroxy-2h-1,2-benzothiazin-s,s-dioxidderivater til brug som mellemprodukter ved fremstilling af 4-hydroxy-3-(5-methyl-3-isoxazolylcarbamoyl)-2-methyl-2h-1,2-benzo-thiazin-1,1-dioxid - Google Patents
4-hydroxy-2h-1,2-benzothiazin-s,s-dioxidderivater til brug som mellemprodukter ved fremstilling af 4-hydroxy-3-(5-methyl-3-isoxazolylcarbamoyl)-2-methyl-2h-1,2-benzo-thiazin-1,1-dioxid Download PDFInfo
- Publication number
- DK148478B DK148478B DK25280A DK25280A DK148478B DK 148478 B DK148478 B DK 148478B DK 25280 A DK25280 A DK 25280A DK 25280 A DK25280 A DK 25280A DK 148478 B DK148478 B DK 148478B
- Authority
- DK
- Denmark
- Prior art keywords
- methyl
- hydroxy
- dioxide
- compound
- formula
- Prior art date
Links
- -1 5-METHYL-3-ISOXAZOLYL CARBAMOYL Chemical class 0.000 title description 22
- 238000002360 preparation method Methods 0.000 title description 7
- 239000000543 intermediate Substances 0.000 title description 4
- HRKBEOWSWBHJNM-UHFFFAOYSA-N 1,1-dioxo-2h-1$l^{6},2-benzothiazin-4-ol Chemical class C1=CC=C2C(O)=CNS(=O)(=O)C2=C1 HRKBEOWSWBHJNM-UHFFFAOYSA-N 0.000 title 1
- GHNLJDPNIAIWOQ-UHFFFAOYSA-N 2h-1$l^{6},2-benzothiazine 1,1-dioxide Chemical compound C1=CC=C2S(=O)(=O)NC=CC2=C1 GHNLJDPNIAIWOQ-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 description 39
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 21
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 19
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 14
- 229910052717 sulfur Inorganic materials 0.000 description 13
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 12
- 229910052739 hydrogen Inorganic materials 0.000 description 9
- 239000002585 base Substances 0.000 description 8
- 238000006243 chemical reaction Methods 0.000 description 8
- 230000020477 pH reduction Effects 0.000 description 8
- 238000000034 method Methods 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- 239000011541 reaction mixture Substances 0.000 description 6
- VAYGXNSJCAHWJZ-UHFFFAOYSA-N dimethyl sulfate Chemical compound COS(=O)(=O)OC VAYGXNSJCAHWJZ-UHFFFAOYSA-N 0.000 description 5
- YYUAYBYLJSNDCX-UHFFFAOYSA-N isoxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC=1C=C(C)ON=1 YYUAYBYLJSNDCX-UHFFFAOYSA-N 0.000 description 5
- 229910052757 nitrogen Inorganic materials 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- RWRDLPDLKQPQOW-UHFFFAOYSA-N tetrahydropyrrole Natural products C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 4
- 230000003110 anti-inflammatory effect Effects 0.000 description 4
- 239000001257 hydrogen Substances 0.000 description 4
- 239000012442 inert solvent Substances 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 239000007858 starting material Substances 0.000 description 4
- DXJICGSIRAJIDN-UHFFFAOYSA-N 2-chloro-N-(5-methyl-3-isoxazolyl)acetamide Chemical compound CC1=CC(NC(=O)CCl)=NO1 DXJICGSIRAJIDN-UHFFFAOYSA-N 0.000 description 3
- FKPXGNGUVSHWQQ-UHFFFAOYSA-N 5-methyl-1,2-oxazol-3-amine Chemical compound CC1=CC(N)=NO1 FKPXGNGUVSHWQQ-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 229910052783 alkali metal Inorganic materials 0.000 description 3
- 230000000202 analgesic effect Effects 0.000 description 3
- 238000002329 infrared spectrum Methods 0.000 description 3
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000012022 methylating agents Substances 0.000 description 3
- 230000001035 methylating effect Effects 0.000 description 3
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 3
- 239000008096 xylene Substances 0.000 description 3
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 229940126062 Compound A Drugs 0.000 description 2
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 230000001754 anti-pyretic effect Effects 0.000 description 2
- 239000002221 antipyretic Substances 0.000 description 2
- 206010003246 arthritis Diseases 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000012043 crude product Substances 0.000 description 2
- 239000012467 final product Substances 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 150000004866 oxadiazoles Chemical class 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 238000005730 ring rearrangement reaction Methods 0.000 description 2
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- CPIFFCMMBZLKDK-UHFFFAOYSA-N 2-methyl-1,1-dioxo-3h-1$l^{6},2-benzothiazin-4-one Chemical compound C1=CC=C2S(=O)(=O)N(C)CC(=O)C2=C1 CPIFFCMMBZLKDK-UHFFFAOYSA-N 0.000 description 1
- GUISUKUVTLQKJU-UHFFFAOYSA-N 2-methyl-1,2-benzothiazin-4-ol Chemical compound C1=CC=C2C(O)=CN(C)SC2=C1 GUISUKUVTLQKJU-UHFFFAOYSA-N 0.000 description 1
- RLQZIECDMISZHS-UHFFFAOYSA-N 2-phenylcyclohexa-2,5-diene-1,4-dione Chemical compound O=C1C=CC(=O)C(C=2C=CC=CC=2)=C1 RLQZIECDMISZHS-UHFFFAOYSA-N 0.000 description 1
- UJVBZCCNLAAMOV-UHFFFAOYSA-N 2h-1,2-benzothiazine Chemical group C1=CC=C2C=CNSC2=C1 UJVBZCCNLAAMOV-UHFFFAOYSA-N 0.000 description 1
- NBICRQSSKKUVNN-UHFFFAOYSA-N 4-hydroxy-1,1-dioxo-2h-1$l^{6},2-benzothiazine-3-carboxylic acid Chemical class C1=CC=C2S(=O)(=O)NC(C(=O)O)=C(O)C2=C1 NBICRQSSKKUVNN-UHFFFAOYSA-N 0.000 description 1
- JQVPAYCOPULQCA-UHFFFAOYSA-N 5-methyl-3h-1,2-oxazol-2-amine Chemical compound CC1=CCN(N)O1 JQVPAYCOPULQCA-UHFFFAOYSA-N 0.000 description 1
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 1
- 206010006811 Bursitis Diseases 0.000 description 1
- VGCXGMAHQTYDJK-UHFFFAOYSA-N Chloroacetyl chloride Chemical compound ClCC(Cl)=O VGCXGMAHQTYDJK-UHFFFAOYSA-N 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- YGYAWVDWMABLBF-UHFFFAOYSA-N Phosgene Chemical compound ClC(Cl)=O YGYAWVDWMABLBF-UHFFFAOYSA-N 0.000 description 1
- 206010036030 Polyarthritis Diseases 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 239000011260 aqueous acid Substances 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 1
- 239000000920 calcium hydroxide Substances 0.000 description 1
- 229910001861 calcium hydroxide Inorganic materials 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 239000011928 denatured alcohol Substances 0.000 description 1
- 239000012065 filter cake Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- BEBCJVAWIBVWNZ-UHFFFAOYSA-N glycinamide Chemical compound NCC(N)=O BEBCJVAWIBVWNZ-UHFFFAOYSA-N 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 150000002431 hydrogen Chemical group 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 239000002085 irritant Substances 0.000 description 1
- 231100000021 irritant Toxicity 0.000 description 1
- 230000000622 irritating effect Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 229910052987 metal hydride Inorganic materials 0.000 description 1
- 150000004681 metal hydrides Chemical class 0.000 description 1
- KNYFJYVFUYERQR-UHFFFAOYSA-N methyl 2-(3-oxo-1,2-benzothiazol-2-yl)acetate Chemical compound C1=CC=C2C(=O)N(CC(=O)OC)SC2=C1 KNYFJYVFUYERQR-UHFFFAOYSA-N 0.000 description 1
- GEUURTZIEGFZAG-UHFFFAOYSA-N methyl 4-hydroxy-1,1-dioxo-2h-1$l^{6},2-benzothiazine-3-carboxylate Chemical compound C1=CC=C2S(=O)(=O)NC(C(=O)OC)=C(O)C2=C1 GEUURTZIEGFZAG-UHFFFAOYSA-N 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- OCEZJTJAJHRHDA-UHFFFAOYSA-N n-(5-methyl-1,2-oxazol-3-yl)-2-(1,1,3-trioxo-1,2-benzothiazol-2-yl)acetamide Chemical compound O1C(C)=CC(NC(=O)CN2S(C3=CC=CC=C3C2=O)(=O)=O)=N1 OCEZJTJAJHRHDA-UHFFFAOYSA-N 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 208000030428 polyarticular arthritis Diseases 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 238000006462 rearrangement reaction Methods 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 229910000104 sodium hydride Inorganic materials 0.000 description 1
- AYGJDUHQRFKLBG-UHFFFAOYSA-M sodium;1,1-dioxo-1,2-benzothiazol-3-olate;dihydrate Chemical compound O.O.[Na+].C1=CC=C2C(=O)[N-]S(=O)(=O)C2=C1 AYGJDUHQRFKLBG-UHFFFAOYSA-M 0.000 description 1
- 239000011877 solvent mixture Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/04—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D261/14—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/20—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D279/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D279/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
- C07D279/02—1,2-Thiazines; Hydrogenated 1,2-thiazines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D281/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one sulfur atom as the only ring hetero atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Description
i 148478 o
Den foreliggende opfindelse angår 4-hydroxy-2H-l,2--benzothiazin-S/S-dioxidderivater til brug som mellemprodukter ved fremstilling af 4-hydroxy-3-(5-methyl-3-isoxazo-lylcarbamoyl)-2-methyl-2H-l,2-benzothiazin-l,1-dioxid, hvil-5 ke derivater er ejendommelige ved, at de har den almene formel C) X) 10 Ύ > ? 0H N-1—CH2CCH3 hvor R betyder hydrogen eller methyl.
Pra beskrivelsen til USA-patent nr. 3.822.258 er 15 det kendt, at 4-hydroxy~3-(5-methyl-3-isozazolylcarbamoyl)- -2-methyl-2H-l,2-benzothiazin-l,l-dioxid og dets analoge, som også har anti-inflammatorisk virkning, kan fremstilles ved omsætning af et f.eks. 2-methylsubstitueret 4-hydroxy--2H-l,2-benzothiazin-3-carboxylat-l,l-dioxid med en f.eks.
20 5-methyl-substitueret 3-aminoisoxazol.
Andre fremgangsmåder til fremstilling af 4-hydroxy--3-(5-methyl-3-isoxazolylcarbamoyl)-2-methyl-2H-l,2-benzo-thiazin-l,l-dioxid er beskrevet i USA patentskrift nr.
3.853.862, hvor et vigtigt mellemprodukt er N-aryl-N'-25 -alkyl-N'-(2'-alkoxycarbamoyl-benzensulfonyl)glycinamid.
Ifølge USA patentskrift nr. 3.821.211 omsættes en pyrrolidinenamin af 3,4-dihydro-2-methyl-4-oxo-2H-l,2--benzothiazin-1,1-dioxid med phosgen og triethylamin, hvorefter den dannede forbindelse omsættes med 3-amino-5-methyl-30 isoxazol, hvorpå der hydrolyseres.
Beslægtede forbindelser med antiinflammatorisk virkning og fremgangsmåder til fremstilling deraf er beskrevet i USA patentskrift nr. 3.591.584 og nr. 3.501.466.
Endvidere er det kendt at fremstille 3-methoxy-35 carbonyl-4-hydroxy-2H-l,2-benzothiazin-l,1-dioxid ud fra 3-oxo-l,2-benzisothiazolin-2-eddikesyremethylester, j fr.
Lombardio et al., J. Med. Chem. 14, 1171-1175 (1971).
O
2 148478
En lignende reaktion, hvor der gås ud fra den analoge methylketon, er beskrevet af Zinnes et al., J. Org.
Chem. 30, 2241-2246 (1965).
Omlejringsreaktioner med substituerede isozazoler 5 og oxadiazoler er generelt beskrevet af H.C. Van Der Pias,
Ring Transformations of Heterocycles, bind 1, kapitel 3, 1973, Academic Press, London, New York.
Stamansøgningen (ans. nr. 2198/76) omhandler en fremgangsmåde til fremstilling af 4-hydroxy-3-(5-methyl-10 -3-isoxazolylcarbamoyl)-2-methyl-2H-l,2-benzothiazin-l,l--dioxid med formlen .0 ,1) 1t.
- ved hvilken a) 3-amino-5-methylisoxazol med formlen 20
Li (II) NH2 25 omsættes med et halogenacetylhalogenid til dannelse af en forbindelse med formlen CH3V% o I || ? (III) 30 ^NH-C-CH2-halogen b) en forbindelse med formlen III omsættes med et salt af saccharin til dannelse af en forbindelse med formlen U8478 3
O
O o \ / <iv) s Vi
^ o /CH
3 c) en forbindelse med formlen IV under dobbelt omlejring 10 omsættes med et alkalimetalalkoxid af en lavere alkohol, fortrinsvis natriummethoxid, i et indifferent opløsningsmiddel, fortrinsvis dimethylformamid, ved en temperatur fra ca. 60 til ca. 70°C efterfulgt af syrning til dannelse af forbindelsen med formlen 15 0. ^0 rY ^nh ? (vi oh n—!L-ch2cch3 20 d) forbindelsen med formlen V methyleres ved omsætning ved en temperatur fra ca. 10 til ca. 25°C med et methyleringsmiddel i et vandigt indifferent opløsningsmiddel indeholdende overskud af base efterfulgt af syrning til 25 dannelse af forbindelsen med formlen ^ ch3 [Ti o (vi) ¥ « 30 OH L1- CH2^CH3 e) forbindelsen med formlen VI under ringomlejring til gendannelse af isoxazolyIringen opvarmes til ca. 100°C med en,fortrinsvis organisk, base, navnlig triethylamin, i 35 et indifferent opløsningsmiddel, fortrinsvis xylen, til dannelse af forbindelsen med formlen I.
4 148478 o
Parallelansøgning nr. 251/80 omhandler fremstilling af den samme forbindelse med formlen i ved, at en forbindelse med formlen CX .0 5 fif |H m OH N-1— CH2CCH3 10 methyleres ved forhøjet temperatur under samtidig eller efterfølgende ringomlejring ved omsætning med et methyleringsmiddel i et ikke-vandigt medium i nærværelse af overskud af base, hvorpå der syrnes.
Forbindelsen med formlen I ovenfor, dvs. 4-hydroxy-15 -3-(5-methyl-3-isoxazolylcarbamoyl)-2-methyl-2H-l,2-benzo- thiazin-1,1-dioxid er således en kendt forbindelse med ønsket antiinflammatorisk, antipyretisk og analgetisk virkning, som dog længe har været ret dyr at lave og kun kan fremskaffes i forholdsvis begrænset omfang. Ved ovennævnte 20 fremgangsmåde ifølge stamansøgningen gås ud fra et let tilgængeligt og billigt udgangsmateriale såsom natriumsaccha-rin, og ved effektive omsætningstrin fås det ønskede slutprodukt med formlen I billigt i rigelig mængde. Forbindelserne med formlen A er mellemprodukter herved, som har 25 formlen V og VI, når R betyder hhv. hydrogen eller methyl (i definitionen til formel A), dvs. idet de da er udgangsstofferne ved trin d) og trin e) ved ovennævnte fremgangsmåde ifølge stamansøgningen.
Tilsvarende gælder for parallelansøgningen, hvor 30 forbindelse A, hvori R er hydrogen, udgør startmaterialet med formlen V, som i ét enkelt trin omlejres og methyleres i benzothiazinringens 2-stilling til dannelse af forbindelsen I.
Omdannelsen af forbindelsen V til forbindelsen VI gennemføres under anvendelse af i og for sig kendt methyle-35 ringsteknik under anvendelse af standardmethyleringsmidler såsom methyliodid og/eller dimethylsulfat i vandige indif-
O
148478 5 ferente opløsningsmidler såsom lavere alkoholer, indeholdende overskud af base. Reaktionstemperaturen reguleres fortrinsvis mellem 10-25°C, da højere temperaturer ikke fører til forbindelsen med formlen VI. Sædvanligvis anvendes 5 overskud, fortrinsvis to ækvivalenter vandig natriumhydroxid med det under navnet "Solvent No. Ill" (SOLOX) forhandlede opløsningsmiddel med et overskud, fortrinsvis 1,5 ækvivalenter dimethylsulfat. SOLOX forhandles af U.S. Industrial Chemical Co. New York, N.Y. og er en generelt anvende-10 lig opløsningsmiddelblanding indeholdende specielt denatureret alkohol med lavt indhold af opløsningsmodificerende stoffer. Ved omrøring af ovennævnte reaktionsblanding i ca. 3 timer ved en temperatur mellem ca. 10°C og 25°C fås efter syrning med en mineralsyre forbindelsen med formlen 15 "ti— CH3 (VI) OH N_Il_CH2CCH3 20 l-{[5-(4-hydroxy-2-methyl-2H-l,2-benzothiazin--3-yl)-1,2,4-oxadiazol-2-yl]methyl}ethanon--S,S-dioxid.
Overføringen af forbindelsen med formlen VI til den 25 tilsigtede forbindelse med formlen I gennemføres ved opvarmning til ca. 100°C i et indifferent opløsningsmiddel, såsom xylen indeholdende en organisk base, fortrinsvis tri-ethylamin, eller ved opvarmning af forbindelsen (VI) til 90-100°C i en vandig base såsom natriumhydroxid, idet dog 30 forbindelsen I så fås efter syrning.
Alternativt kan forbindelsen med formlen V omdannes til forbindelsen med formlen (I) under anvendelse af konventionelle methyleringsmidler i vandige alkoholer indeholdende overskud af base ved forhøjet temperatur. Forbin-35 delsen med formlen (V) kan eksempelvis anbringes i SOLOX
indeholdende overskud, fortrinsvis 3,5 ækvivalenter, af van-
O
6 148478 dig natriumhydroxid med et overskud, fortrinsvis 1,5 ækvivalenter, af dimethylsulfat, og opvarmes til tilbagesvaling (ca. 75-80°C) i ca. 1 1/2 time. Efter syrning fås forbindelsen med formlen (I).
5 Hensigtsmæssig kan forbindelsen med formlen (V) omdannes til forbindelsen med formlen (I) i et vandfrit medium såsom dimethylformamid ved forhøjet temperatur (ca. 50 til ca. 80°C) fortrinsvis 60°C, under anvendelse af overskud, fortrinsvis to ækvivalenter af en metalhydrid-10 base, fortrinsvis natriumhydrid, efterfulgt af tilsætning af et konventionelt methyleringsmiddel, såsom methyliodid.
Ved syrning.fås forbindelsen med formlen (I).
De tilsvarende alkalimetalsalte, jordalkalimetal-salte og aminsalte af forbindelsen med formlen (I) kan 15 fremstilles ved at behandle forbindelsen med fomlen (I) med den ønskede base, f.eks. natriumalkoxid, kaliumalkoxid, natriumhydroxid, kaliumhydroxid, calciumhydroxid, pyrroli-din og lignende på i og for sig kendt måde. Eventuelt kan det ønskede alkalimetalsalt af forbindelsen (I) fås direkte 20 ved udeladelse af syrningsreaktionen i det sidste procestrin .
Det ifølge stamansøgningen anvendte udgangsmateriale, 2-amino-5-methylisoxazol med formlen (II) er kendt og kan fremstilles som beskrevet i beskrivelsen til hol-25 landsk patent nr. 6.511.924, men er iøvrigt kommercielt tilgængeligt fra firmaet Hoffmann La Roche, Nutley, New Jersey. ,
Forbindelsen med formlen (I) er kendt fra beskrivelsen til USA patent nr.'3.816.628 som en forbindelse med 30 antiinflammatorisk, antipyretisk og analgetisk virkning.
Ved oral indgift til rotter i en dosis på 10-200 mg/kg kan den bevirke formindskelse af potehævning fremkaldt ved injektion i trædepuderne med et irriterende stof såsom car-rageenin. Ved oral, terapeutisk eller profylaktisk indgift 35 i en mængde på 15-200 mg/kg inhiberer forbindelsen polyarthritis hos rotter induceret med et hjælpestof, Orale
O
148478 7 doser på 25-100 mg/kg er tilstrækkelig til at inhibere gærinduceret hyperterrai hos rotter. Ved orale doser på 25-200 mg/kg udviser stoffet en signifikant analgetisk virkning bestemt ved phenylquinonvridningstesten på mus.
c
Generelt vil forbindelsen med formlen I indiceres ved tilstande såsom smerter fremkaldt af arthritis, bursitis og lignende. En daglig dosis på ca. 0,5 g til ca. 2 g opdelt i flere doser anbefales til pattedyr med en legemsvægt på ca. 70 kg til at lindre smerten og hævningen for-10 bundet med disse tilstande og kan indgives enten oralt eller ved injektion.
Opfindelsen forklares nærmere i de følgende eksempler, hvor eksempel 1-3/4 beskriver fremstillingen af forbindelse A, hvori R er hydrogen/methyl, og eksempel 4/5-7 15 beskriver anvendelsen heraf til fremstilling af det aktive slutprodukt med formelen I.
Eksempel 1 20 CH3v0^ I_i ? (i) NH-C-CH2C1 3- (Chloracetamido)-5-methylisoxazol 25
Til 800 ml chloroform sættes 118 g (1,12 mol) 3--amino-5-methylisoxazol efterfulgt af 118 g (1,5 mol) pyri-din. Til denne opløsning sættes 147 g (1,3 mol) chlorace-tylchlorid, idet temperaturen holdes på 0-10°C. Reaktionsblandingen omrøres derefter ved stuetemperatur i 1 time, 30 ' filtreres og tørres i en vakuumekssikkator, hvorved fås 116 g (56%) 3-(chloracetamido)-5-methylisoxazol med smp. 192-195°C. Dette materiale har en let irriterende virkning på huden og skal derfor omgås med behørig forsigtighed.
Analyse for CgH^ClN-jC^ (174,58): 35 C% H% N%. Cl%
Beregnet 41,28 4,04 16,05 20,31
Fundet 41,55 4,10 15,79 20,50 148478 8
O
V°
Eksempel 2 6 I SK ^C-NH (IV)
"TT
^0 ch3 2,3-Dihydro-N-(5-methyl-3-isoxazolyl)-3-oxo-l,2-benzisathia- 10 zol-2-acetamid-l,l-dioxid (IV)_
Til 2,31 liter DMF sættes 479 g (2,75 mol) 3-(chlor-acetamido)-5-methylisoxazol og derpå 699 g (2,9 mol) na-triumsaccharin-dihydrat. Blandingen opvarmes til 100°C, og denne temperatur holdes i 2 timer. Den afkølede reaktions-15 blanding hældes i 8 liter vand, filtreres, og den våde filterkage omkrystalliseres af 15 liter ethanol, hvorved fås 658 g (74,8%) 2,3-dihydro-N-(5-methyl-3-isoxazolyl)-3-oxo--l,2-benzisothiazol-2-acetamid-l,l-dioxid med smp. 218-220°C.
IR- og NMR-spektrene stemmer overens med strukturen.
on
Analyse for ci3HnN3°5S (321,30): C% H% N% S%
Beregnet 48,60 3,45 13,08 9,98
Fundet 48,62 3,61 13,28 10,19 25
Eksempel 3
CX
^ V*
T\/ XNH
30 L. JL JL
N o {v) OH P I π N_11-CH2CCH3 l-{[5-(4-Hydroxy-2H-l,2-benzothiazin-3-yl)-1,2,4-oxadiazol- 35 il -yl]methyl)ethanon-S,S-dioxid (V)_
Til 300 ml DMF sættes 67,5 g (1,25 mol) natrium-methoxid. Blandingen opvarmes til 55°C, hvorefter der til-
O
148478 9 sættes en opløsning af 100 g (0,31 mol) 2,3-dihydro-N-(5--methyl-3-isoxazolyl)-3-oxo-l,2-benzisothiazol-2-acetamid--1,1-dioxid i 350 ml DMF. Temperaturen holdes på 60-70°C i 1/2 time, hvorefter blandingen hældes i vandig syre. Der fås 5 71 g (71%) råprodukt med formlen(V).
Stoffet renses ved behandling med varm vandig methanol, hvorved fås l-{[5-(4-hydroxy-2H-l,2-benzothiazin-3--yl)-1,2,4-oxadiazol-3-yl]methyl}·ethanon-S,S-dioxid med smp. 187-189°C. IR- og NMR-spektrene stemmer overens med 10 strukturen.
Analyse for C]_3H]_]_N3°5S (321,30): C% H% N% S%
Beregnet 48,60 3,45 13,08 9,98
Fundet 48,55 3,49 12,93 10,16.
15
Eksempel 4 °W° CH3 20 L 1 (VI) ' Il i ® nti M I 11 N_!J_ CH2CCH3 l-{[5-(4-Hydroxy-2-methyl-2H-l,2-benzothiazin-3-yl)-1,2,4- 25 -oxadiazol-3-yl]methyl3~ethanon-S,S-dioxid (VI)_
Til 160 ml 56%'s vandig "Solvent No. 3" (SOLOX) sættes 3,21 g (0,01 mol) 1-{[5-(4-hydroxy~2H-l,2-benzothiazin--3-yl)-1,2,4-oxadiazol-3-yl]-methyl^ethanon-S,S-dioxid, og blandingen afkøles til 5°C, hvorefter der dråbevis tilsæt-30 tes 20 ml 1 N natriumhydroxidopløsning, idet temperaturen holdes under 10°C. Til denne blanding sættes 1,8 g (0,015 mol) dimethylsulfat, og reaktionsblandingen omrøres i 3 timer med en maksimaltemperatur på 25°C. Derpå syrnes med 6N saltsyre, hvorved fås 2,8 g (85%) analytisk rent l--f[5-35 ^ -(4-hydroxy-2-methyl-2H-l,2-benzothiazin-3-yl)-1,2,4-oxadia- U8478 10 o zol-3-yl]methylJ.ethanon-S,S-dioxid med smp. 143-145°C. IR-og NMR-spektrene er i overensstemmelse med strukturen.
Analyse for (335,32) : C% H% N% S% 5 Beregnet 50,15 3,91 12,53 9,56
Fundet 49,97 3,98 12,52 9,72
Eksempel 5 v 10 >V'N-^'CH3 L (i>
, CNH
“ s V-i 15 ν\0Ά CH3 4-Hydroxy-3-(5-methyl-3-isoxazolylcarbamoyl)-2-methyl-2H- -1,2-benzothiazin-l,l-dioxid (I)_
Til 80 ml xylen sættes 4,0 g (0,012 mol) 1-^(5-(4-20 -hydroxy-2-methyl-2H-l,2-benzothiazin-3-yl)-l,2,4-oxadia- zol-3-yl]methyl}ethanon-S,S-dioxid og derpå 0,4 g (0,0046 mol) triethylamin, og temperaturen indstilles på 115-120°C i 30 minutter. Reaktionsblandingen afkøles og filtreres, hvorved fås 3,6 g (90%) 4-hydroxy-3-(5-methyl-3-isoxazolyl-25 carbamoyl)-2-methyl-2H-l,2-benzothiazin-l,l-dioxid med smp.
252-254°C.
Analyse for ci4Hi3N305S (335,32): C% H% N% S% 30 Beregnet 50,15 3,91 12,53 9,56
Fundet 49,96 3,95 12,47 9,58 11
O
148478
Eksempel 6 ^CH3 (I) I II ^-r
OH O |l I
N\ A
o ch3 4-Hydroxy-3-(5-methyl-3-isoxazolylcarbamoyl)-2-methyl-2H- 10 -l,2-benzothiazin-l,l-dioxid (I)_
Til 20 ml DMF sættes 3,2 g (10 millimol) af den ikke-alkylerede oxadiazol, 1--((5-(4-hydroxy-2H-l,2-benzo- thiaz in-3-yl)-1,2,4-oxadiazol-3-y1]methyl^ethanon-S,S-di- oxid. Til denne blanding sættes 0,9 g 57%'s NaOH (21,4 mil-15 q limol), og temperaturen stiger til 60 C. Temperaturen får lov til at aftage af sig selv til 25°C, hvorefter der tilsættes 1,4 g (10 millimol) methyliodid opløst i 1 ml di-methylformamid. Reaktionsblandingen opvarmes til 60°C i ^ 2 timer, afkøles og syrnes, hvorved fås 2,3 g (70%) af et materiale, hvis tyndtlagschromatogram svarer til tyndtlags-chromatogrammet for 4-hydroxy-3-(5-methyl-3-isoxazolylcarba-moyl)-2-methyl-2H-l,2-benzothiazin-l,1-dioxid fremstillet ifølge eksempel 5.
25
Eksempel 7 NN-CT3 I (I)
30 CNH
0H n A-
N I
CH3 Ο 12 148470 4-Hydroxy-3-(5-methyl-3-isoxazolylcarbamoyl)-2-methyl-2H- -l,2-benzothiazin-l,l-dioxid (I)_
Til 60 ml SOLOX sættes 3,21 g (0,01 mol) 1-^(5-(4--hydroxy-2H-l,2-benzothiazin-3-yl)-1,2,4-oxadiazol-3-yl]-5 methyl} ethanon-S,S-dioxid efterfulgt af 35 ml 1 N"natriumhydroxidopløsning. Til denne blanding sættes 1,89 g (0,015 mol) dimethylsulfat, og reaktionen opvarmes til tilbagesvaling (75-80°C) i 1 og 1/2 time. Ved afkøling og filtrering fås 2,3 g (70%) af råproduktet I. Ved rensning (DMF/-10 SOLOX omkrystallisation fås 4-hydroxy-3-(S-methyl-S-isoxa- zolylcarbamoyl) -2-methyl-2H-l,2-benzothiazin-l,1-dioxid med smp. 247-250°C (sønderdeling), hvis tyndtlagschromato-gram er identisk med tyndtlagschromatogrammet for materialet fremstillet direkte ud fra 1--^(5-(4-hydroxy-2-methy1-15 -2H-l,2-benzothiazin-3-yl)-l,2^4-oxadiazol-3-yl]methyl^- ethanon-S,S-dioxid i eksempel 5.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US57756875 | 1975-05-21 | ||
US05/577,568 US3957772A (en) | 1975-05-21 | 1975-05-21 | Process for the preparation of 4-hydroxy-3-(5-methyl-3-isoxazolylcarbamoyl)-2-methyl-2h-1,2-benzothiazine 1,1-dioxide |
Publications (3)
Publication Number | Publication Date |
---|---|
DK25280A DK25280A (da) | 1980-01-22 |
DK148478B true DK148478B (da) | 1985-07-15 |
DK148478C DK148478C (da) | 1985-12-16 |
Family
ID=24309281
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK219876A DK148479C (da) | 1975-05-21 | 1976-05-19 | Fremgangsmaade til fremstilling af 4-hydroxy-3-(5-methyl-3-isoxazolylcarbamoyl)-2-methyl-2h-1,2-benzothiazin-1,1-dioxid |
DK25280A DK148478C (da) | 1975-05-21 | 1980-01-22 | 4-hydroxy-2h-1,2-benzothiazin-s,s-dioxidderivater til brug som mellemprodukter ved fremstilling af 4-hydroxy-3-(5-methyl-3-isoxazolylcarbamoyl)-2-methyl-2h-1,2-benzo-thiazin-1,1-dioxid |
DK25180A DK149752C (da) | 1975-05-21 | 1980-01-22 | Fremgangsmaade til fremstilling af 4-hydroxy-3-(5-methyl-3-isoxazolylcarbamoyl)-2-methyl-2h-1,2-benzothiazin-1,1-dioxid |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK219876A DK148479C (da) | 1975-05-21 | 1976-05-19 | Fremgangsmaade til fremstilling af 4-hydroxy-3-(5-methyl-3-isoxazolylcarbamoyl)-2-methyl-2h-1,2-benzothiazin-1,1-dioxid |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK25180A DK149752C (da) | 1975-05-21 | 1980-01-22 | Fremgangsmaade til fremstilling af 4-hydroxy-3-(5-methyl-3-isoxazolylcarbamoyl)-2-methyl-2h-1,2-benzothiazin-1,1-dioxid |
Country Status (10)
Country | Link |
---|---|
CH (1) | CH629802A5 (da) |
DK (3) | DK148479C (da) |
ES (1) | ES448088A1 (da) |
FI (1) | FI63230C (da) |
IE (1) | IE43102B1 (da) |
IN (1) | IN143577B (da) |
MX (1) | MX3139E (da) |
NO (1) | NO145917C (da) |
PH (2) | PH14848A (da) |
SE (2) | SE429043B (da) |
-
1976
- 1976-03-30 IN IN548/CAL/76A patent/IN143577B/en unknown
- 1976-05-04 IE IE947/76A patent/IE43102B1/en unknown
- 1976-05-10 MX MX000219U patent/MX3139E/es unknown
- 1976-05-17 PH PH18443A patent/PH14848A/en unknown
- 1976-05-19 DK DK219876A patent/DK148479C/da active
- 1976-05-20 SE SE7605752A patent/SE429043B/xx not_active IP Right Cessation
- 1976-05-20 NO NO761724A patent/NO145917C/no unknown
- 1976-05-20 ES ES448088A patent/ES448088A1/es not_active Expired
- 1976-05-20 FI FI761431A patent/FI63230C/fi not_active IP Right Cessation
- 1976-05-21 CH CH642776A patent/CH629802A5/de not_active IP Right Cessation
-
1980
- 1980-01-22 DK DK25280A patent/DK148478C/da active
- 1980-01-22 DK DK25180A patent/DK149752C/da not_active IP Right Cessation
- 1980-03-03 SE SE8001649A patent/SE447112B/sv not_active IP Right Cessation
-
1981
- 1981-01-28 PH PH25141A patent/PH16804A/en unknown
Also Published As
Publication number | Publication date |
---|---|
DK25280A (da) | 1980-01-22 |
DK25180A (da) | 1980-01-22 |
DK148479B (da) | 1985-07-15 |
IE43102B1 (en) | 1980-12-17 |
SE429043B (sv) | 1983-08-08 |
SE7605752L (sv) | 1976-11-22 |
CH629802A5 (en) | 1982-05-14 |
ES448088A1 (es) | 1977-07-01 |
DK219876A (da) | 1976-11-22 |
SE8001649L (sv) | 1980-03-03 |
FI63230B (fi) | 1983-01-31 |
NO145917C (no) | 1982-06-23 |
MX3139E (es) | 1980-05-06 |
DK149752C (da) | 1987-03-16 |
NO761724L (da) | 1976-11-23 |
FI761431A (da) | 1976-11-22 |
DK148479C (da) | 1985-12-16 |
DK149752B (da) | 1986-09-22 |
IE43102L (en) | 1976-11-21 |
FI63230C (fi) | 1983-05-10 |
NO145917B (no) | 1982-03-15 |
DK148478C (da) | 1985-12-16 |
PH14848A (en) | 1982-01-06 |
SE447112B (sv) | 1986-10-27 |
IN143577B (da) | 1977-12-31 |
PH16804A (en) | 1984-03-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US4397853A (en) | Isoxazole derivatives | |
US4476137A (en) | [1-(2-Benzoxazolyl)hydrazino]alkyl nitrile derivatives | |
BG60475B2 (bg) | 4-хидрокси-2н-1,2-бензотиазин-3-карбоксамид-1,1-диоксиди, метод за получаването им и лекарствени средства,които ги съдържат | |
JP2004359676A (ja) | 置換チアゾリジンジオン誘導体 | |
JPH0283384A (ja) | 新規化合物、その製法及びそれを含む医薬組成物 | |
PT605228E (pt) | Derivados tiazolidinadionas sua preparacao e sua utilizacao | |
KR900004126B1 (ko) | 아릴피페라지닐-에틸(또는 부틸)-페닐-헤테로시클릭 화합물 | |
US4018762A (en) | Process for the preparation of 4-hydroxy-3-(5-methyl-3-isoxazolylcarbamoyl)-2-methyl-2H-1,2-benzothiazine 1,1-dioxide | |
EP0259085B1 (en) | 2-guanidino-4-arylthiazoles for treatment of peptic ulcers | |
US3987038A (en) | Process for the preparation of {1-[5-(4-hydroxy-2H-1,2-benzothiazin-3-yl)-1,2,4-oxadiazol-3-yl]methyl}ethanone S,S-dioxide | |
JPS58128384A (ja) | ベンゾジオキシン化合物、その製造方法、および精神作用障害治療用医薬組成物 | |
DK148478B (da) | 4-hydroxy-2h-1,2-benzothiazin-s,s-dioxidderivater til brug som mellemprodukter ved fremstilling af 4-hydroxy-3-(5-methyl-3-isoxazolylcarbamoyl)-2-methyl-2h-1,2-benzo-thiazin-1,1-dioxid | |
US4246272A (en) | Benzamidine derivatives | |
JPH01156966A (ja) | リポキシゲナーゼ抑制作用を有するピリダジノン、トリアジノンおよびオキサピリダジノン化合物 | |
US4065617A (en) | 2-(2,2,2,-Trifluoroethyl)-3,3a,4,5,6,7-hexahydro-2H-pyrazolo[4,3-c]pyridines | |
US4041042A (en) | Intermediate composition | |
JPH0440348B2 (da) | ||
US2948731A (en) | Derivatives of thiazoline-2-ones | |
US3978073A (en) | 3-(Chlorocetamido)-5-methyl isoxazole | |
JPS6340190B2 (da) | ||
JPS6035344B2 (ja) | チアゾリジン誘導体の製造方法 | |
HU194872B (en) | Process for production of pirasole-derivatives and medical preparatives containing them | |
US3890331A (en) | 3-Substituted-5-hydroxy (mercapto) alkylidene-rhodanine derivatives | |
JPS5929583B2 (ja) | 新規フエニル酢酸誘導体の製造法 | |
JPS61218587A (ja) | 5−〔3−(9−エチル)カルバゾリル〕テトラゾ−ル及びその製造方法 |